Earnings Preview: 10x Genomics to Report Financial Results Post-market on October 29
$10x Genomics(TXG.US)$ is scheduled to release its financial results post-market on October 29 ET. Earnings PreviewAnalysts estimate $10x Genomics(TXG.US)$ to post revenue of USD151.67M for 2024Q3,
10x Genomics (TXG) Upgraded to Strong Buy: Here's Why
Genoa Ventures Elevates Landon Merrill to Partner, Strengthening Leadership in Science-Driven Investing
PacBio Onso Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program
Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
Proteintech Genomics Launches the MultiPro Human Discovery Panel: A New Frontier in Single-Cell Multiomics
European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics Against NanoString's CosMx SMI Products
Leerink Partners Maintains 10x Genomics(TXG.US) With Buy Rating
TD Cowen Maintains 10x Genomics(TXG.US) With Hold Rating, Cuts Target Price to $18
Strategic Pricing and Market Expansion Drive 10x Genomics Buy Rating
TD Cowen Reaffirms Their Hold Rating on 10x Genomics (TXG)
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $21
10x Genomics Delivers 'Single Cell for a Single Cent' With New Chromium Launches
10x Genomics Is Maintained at Overweight by Barclays
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $21
Trending Stocks in Another Record Week for Wall Street
Single-cell Technologies Research Report 2023-2024 & 2029 10x Genomics, Agilent Technologies, BD, Bio-Rad Laboratories, Danaher, Illumina, Merck, Promega, Qiagen, & Thermo Fisher Scientific - ResearchAndMarkets.com
Temporary Disruption at 10x Genomics: A Buy Rating Amidst Sales Force Realignment and Strong Product Fundamentals
Small U.S. Stocks Close Lower; 10x Genomics Takes Biggest Hit
Wolfe's Tax Loss Selling Stocks Within Communications, Discretionary, Staples, Energy, Financials, Health Care